Evidence map›Paper›PMID 38568950›Full record

ArticlePloS one2024

Quantifying intra-tumoral genetic heterogeneity of glioblastoma toward precision medicine using MRI and a data-inclusive machine learning algorithm.

Lujia Wang, Hairong Wang, Fulvio D'Angelo, Lee Curtin, Christopher P Sereduk, Gustavo De Leon, Kyle W Singleton, Javier Urcuyo, Andrea Hawkins-Daarud, Pamela R Jackson and 15 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Artificial Intelligence-Driven Multi-Omics Approaches in Glioblastoma.International journal of molecular sciences · 2025
    Review
  6. Article
  7. Review
  8. Knowledge-Informed Machine Learning for Cancer Diagnosis and Prognosis: A Review.IEEE transactions on automation science and engineering : a publication of the IEEE Robotics and Automation Society · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 5 institutions in 2 countries.

Lujia WangH. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, Georgia, United States of America.
Hairong WangH. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, Georgia, United States of America.
Fulvio D'AngeloInstitute for Cancer Genetics, Columbia University Medical Center, New York City, New York, United States of America.ORCID 0000-0002-4940-4693
Lee CurtinDepartment of Neurosurgery, Mayo Clinic Arizona, Phoenix, Arizona, United States of America.
Christopher P SeredukDepartment of Neurosurgery, Mayo Clinic Arizona, Phoenix, Arizona, United States of America.
Gustavo De LeonDepartment of Neurosurgery, Mayo Clinic Arizona, Phoenix, Arizona, United States of America.
Kyle W SingletonDepartment of Neurosurgery, Mayo Clinic Arizona, Phoenix, Arizona, United States of America.ORCID 0000-0002-9969-8474
Javier UrcuyoDepartment of Neurosurgery, Mayo Clinic Arizona, Phoenix, Arizona, United States of America.
Andrea Hawkins-DaarudDepartment of Neurosurgery, Mayo Clinic Arizona, Phoenix, Arizona, United States of America.
Pamela R JacksonDepartment of Neurosurgery, Mayo Clinic Arizona, Phoenix, Arizona, United States of America.
Chandan KrishnaDepartment of Neurosurgery, Mayo Clinic Arizona, Phoenix, Arizona, United States of America.
Richard S ZimmermanDepartment of Neurosurgery, Mayo Clinic Arizona, Phoenix, Arizona, United States of America.
Devi P PatraDepartment of Neurosurgery, Mayo Clinic Arizona, Phoenix, Arizona, United States of America.
Bernard R BendokDepartment of Neurosurgery, Mayo Clinic Arizona, Phoenix, Arizona, United States of America.
Kris A SmithDepartment of Neurosurgery, Barrow Neurological Institute-St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States of America.
Peter NakajiDepartment of Neurosurgery, Barrow Neurological Institute-St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States of America.ORCID 0000-0001-6677-2925
Kliment DonevDepartment of Pathology, Mayo Clinic Arizona, Phoenix, Arizona, United States of America.ORCID 0009-0000-4221-0936
Leslie C BaxterDepartment of Neuropsychology, Mayo Clinic Arizona, Phoenix, Arizona, United States of America.
Maciej M MrugałaDepartment of Neuro-Oncology, Mayo Clinic Arizona, Phoenix, Arizona, United States of America.
Michele CeccarelliDepartment of Electrical Engineering and Information Technology, University of Naples "Federico II", Naples, Italy.
Antonio IavaroneInstitute for Cancer Genetics, Columbia University Medical Center, New York City, New York, United States of America.
Kristin R SwansonDepartment of Neurosurgery, Mayo Clinic Arizona, Phoenix, Arizona, United States of America.
Nhan L TranDepartment of Neurosurgery, Mayo Clinic Arizona, Phoenix, Arizona, United States of America.
Leland S HuDepartment of Radiology, Mayo Clinic Arizona, Phoenix, Arizona, United States of America.
Jing LiH. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, Georgia, United States of America.ORCID 0000-0001-7028-3681
Mayo Clinic Hospital · USGeorgia Institute of Technology · USBarrow Neurological Institute · USColumbia University Irving Medical Center · USUniversity of Naples Federico II · IT

Funding

Outreach CoreU54CA274504 · NCI · MAYO CLINIC ARIZONA · PI Kristin R Swanson · 2023 to 2026
$8.6M
Quantifying Multiscale Competitive Landscapes of Clonal Diversity in GlioblastomaU01CA220378 · NCI · MAYO CLINIC ARIZONA · PI HU, LELAND, MITCHELL, JOSEPH ROSS · 2017 to 2021
$4.3M
Langworthy Diversity Supplement: Image-based models of tumor-immune dynamics in glioblastomaU01CA250481 · NCI · MAYO CLINIC ARIZONA · PI CANOLL, PETER, HU, LELAND · 2021 to 2025
$3.8M
NCI NIH HHS U01 CA220378NCI NIH HHS U01 CA250481NCI NIH HHS U54 CA274504
6 · The paper itself

Abstract

BACKGROUND AND

objectiveGlioblastoma (GBM) is one of the most aggressive and lethal human cancers. Intra-tumoral genetic heterogeneity poses a significant challenge for treatment. Biopsy is invasive, which motivates the development of non-invasive, MRI-based machine learning (ML) models to quantify intra-tumoral genetic heterogeneity for each patient. This capability holds great promise for enabling better therapeutic selection to improve patient outcome.

methodsWe proposed a novel Weakly Supervised Ordinal Support Vector Machine (WSO-SVM) to predict regional genetic alteration status within each GBM tumor using MRI. WSO-SVM was applied to a unique dataset of 318 image-localized biopsies with spatially matched multiparametric MRI from 74 GBM patients. The model was trained to predict the regional genetic alteration of three GBM driver genes (EGFR, PDGFRA and PTEN) based on features extracted from the corresponding region of five MRI contrast images. For comparison, a variety of existing ML algorithms were also applied. Classification accuracy of each gene were compared between the different algorithms. The SHapley Additive exPlanations (SHAP) method was further applied to compute contribution scores of different contrast images. Finally, the trained WSO-SVM was used to generate prediction maps within the tumoral area of each patient to help visualize the intra-tumoral genetic heterogeneity.

resultsWSO-SVM achieved 0.80 accuracy, 0.79 sensitivity, and 0.81 specificity for classifying EGFR; 0.71 accuracy, 0.70 sensitivity, and 0.72 specificity for classifying PDGFRA; 0.80 accuracy, 0.78 sensitivity, and 0.83 specificity for classifying PTEN; these results significantly outperformed the existing ML algorithms. Using SHAP, we found that the relative contributions of the five contrast images differ between genes, which are consistent with findings in the literature. The prediction maps revealed extensive intra-tumoral region-to-region heterogeneity within each individual tumor in terms of the alteration status of the three genes.

conclusionsThis study demonstrated the feasibility of using MRI and WSO-SVM to enable non-invasive prediction of intra-tumoral regional genetic alteration for each GBM patient, which can inform future adaptive therapies for individualized oncology.

Indexed as

GlioblastomaAlgorithmsErbB ReceptorsGenetic HeterogeneityHumansMachine LearningMagnetic Resonance ImagingPrecision MedicineSupport Vector MachineErbB Receptors

Identifiers

PMID38568950
PMCPMC10990246
OpenAlexW4393865552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.